Studies have shown that Spectinabilin (1) exerts anti-tumor effects against SMMC7721 and HepG2 cells by down-regulating the PI3K/AKT signaling pathway, which is involved in a series of processes such as cell proliferation, tumorigenesis, and development. Here, AKT1 is linked to neoplasm.